Evidence map›Paper›PMID 41608569›Full record

ArticleTheranostics2026

Tumor cell FAP orchestrates EMT and immune suppression in aggressive localized ccRCC.

Teijo Pellinen, Lassi Luomala, Kalle E Mattila, Annabrita Hemmes, Katja Välimäki, Mariliina Arjama, Oscar Brück, Lassi Paavolainen, Elisa Kankkunen, Harry Nisén and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Teijo PellinenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Lassi LuomalaDepartment of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Kalle E MattilaDepartment of Oncology and Radiotherapy, FICAN West Cancer Centre, University of Turku, Turku University Hospital, Turku, Finland.
Annabrita HemmesInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Katja VälimäkiInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Mariliina ArjamaInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Oscar BrückHematoscope Lab, Comprehensive Cancer Center & Center of Diagnostics, Helsinki University Hospital, Helsinki, Finland & Department of Oncology, University of Helsinki, Helsinki, Finland.
Lassi PaavolainenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Elisa KankkunenDepartment of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Harry NisénDepartment of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Petrus JärvinenDepartment of Urology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Leticia CastillonTranslational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Sakari VanharantaTranslational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Paula VainioDepartment of Pathology, Turku University Hospital, University of Turku, Turku, Finland.
Olli KallioniemiInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) and iCAN - Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
Panu M JaakkolaDepartment of Oncology and Radiotherapy, FICAN West Cancer Centre, University of Turku, Turku University Hospital, Turku, Finland.
Tuomas MirttiDepartment of Pathology, Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellEpithelial-Mesenchymal TransitionGelatinasesKidney NeoplasmsMembrane ProteinsSerine EndopeptidasesBiomarkers, TumorEndopeptidasesFemaleFibroblast Activation Protein AlphaHumansMalePrognosisStromal CellsTumor MicroenvironmentBiomarkers, TumorEndopeptidasesFibroblast Activation Protein AlphaGelatinasesMembrane ProteinsSerine Endopeptidasesclear cell renal cell carcinomaepithelial-to-mesenchymal transitionFAPspatial immunosuppressiontumor microenvironment

Identifiers

PMID41608569
PMCPMC12846009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.